Phil is a nuclear pharmacist with more than 10 years of experience from Progenics, Baxter, Sanofi, New York University and Memorial Sloan-Kettering Cancer Center. He was the CMC-Regulatory lead on multiple submissions to U.S. Food and Drug Administration for theranostic products from pre-IND through approval and post-marketing. He has also designed and built cGMP manufacturing facilities and initiated and led the quality and regulatory functions. Notable products he has supported are 18-F-PyL (Pyalarify); I-131 8H9 / 3F8 (naxitamab); and Sutimlimab (Enjaymo®). He was previously the regulatory advisor and cofounder of Evergreen Theragnostics. He earned a B.S. from the University of Central Florida and a PharmD from the Massachusetts College of Pharmacy and Health.